Succinobucol (CAS 216167-82-7)
See product citations (1)
QUICK LINKS
Succinobucol is a unique synthetic antioxidant that operates through a mechanism of action centered around its ability to scavenge free radicals and inhibit the oxidation of low-density lipoprotein (LDL), a critical process in the pathogenesis of atherosclerosis. Beyond its direct antioxidative properties, succinobucol also exhibits anti-inflammatory effects by modulating the activity of key enzymes and transcription factors involved in inflammatory pathways. In research applications, succinobucol has been extensively studied for its potential to provide insights into the molecular mechanisms underpinning oxidative stress-related cellular damage and inflammation. Its role in the investigation of cardiovascular diseases, particularly in the study of atherosclerosis, highlights its importance as a tool for understanding the complex interplay between oxidative stress, inflammation, and vascular pathology.
Succinobucol (CAS 216167-82-7) References
- Probucol and succinobucol in atrial fibrillation: pros and cons. | Liu, T. and Li, G. 2010. Int J Cardiol. 144: 295-6. PMID: 19278740
- AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. | Crim, WS., et al. 2010. Mol Cell Endocrinol. 323: 246-55. PMID: 20211684
- Succinobucol induces apoptosis in vascular smooth muscle cells. | Midwinter, RG., et al. 2012. Free Radic Biol Med. 52: 871-9. PMID: 22203369
- Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism. | Jurček, O., et al. 2012. J Pharm Sci. 101: 1794-802. PMID: 22323097
- Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. | Watt, J., et al. 2013. Catheter Cardiovasc Interv. 81: 698-708. PMID: 22581717
- Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro. | Colle, D., et al. 2013. Mitochondrion. 13: 125-33. PMID: 23333792
- New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action. | Ladopoulou, E., et al. 2013. J Med Chem. 56: 3330-8. PMID: 23581491
- Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. | Cao, H., et al. 2015. J Control Release. 205: 162-71. PMID: 25598420
- Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. | Colle, D., et al. 2016. Mol Neurobiol. 53: 1280-1295. PMID: 25619973
- Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease. | Santos, DB., et al. 2017. Mol Neurobiol. 54: 1513-1530. PMID: 26852411
- A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. | Dan, Z., et al. 2016. Theranostics. 6: 435-45. PMID: 26909117
- Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia. | Ribeiro, RP., et al. 2016. Behav Brain Res. 305: 30-6. PMID: 26921691
- An investigation of the antiplatelet effects of succinobucol (AGI-1067). | Houston, SA., et al. 2017. Platelets. 28: 295-300. PMID: 27681689
- Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials. | Boczar, KE., et al. 2022. BMJ Open. 12: e062702. PMID: 35760536
- PLGA Nanoparticles Containing VCAM-1 Inhibitor Succinobucol and Chemotherapeutic Doxorubicin as Therapy against Primary Tumors and Their Lung Metastases. | Wang, J., et al. 2023. Pharmaceutics. 15: PMID: 36839671
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Succinobucol, 50 mg | sc-391465 | 50 mg | $360.00 | |||
Succinobucol, 100 mg | sc-391465A | 100 mg | $573.00 | |||
Succinobucol, 250 mg | sc-391465B | 250 mg | $1380.00 | |||
Succinobucol, 500 mg | sc-391465C | 500 mg | $2290.00 |